BOSTON SCIENTIFIC CORPORATION Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount
BOSTON SCIENTIFIC CORPORATION (BSX) reported Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount of $65.00 million for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Notes › Investments › Debt and Equity Securities
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount · last filed 2020-11-05
- BOSTON SCIENTIFIC CORPORATION equity securities without readily determinable fair value, upward price adjustment, annual amount for the quarter ending 2020-09-30 was $65.00M.
| Period end | Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount 3 month |
|---|---|
| 2020-09-30 | $65.00M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BECTON DICKINSON & CO (BDX) | United States | $48.834B | 43.79 |
| 3M CO (MMM) | United States | $86.404B | 27.87 |
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| WEST PHARMACEUTICAL SERVICES INC (WST) | United States | $26.288B | 43.14 |
| STRYKER CORP (SYK) | United States | $103.511B | 32.39 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |